Abstract and Introduction
Background: Lack of biomarkers for treatment selection and monitoring in small cell lung cancer (SCLC) patients with the limited therapeutic options, result in poor outcomes. Therefore, new prognostic biomarkers are needed to improve their management. The prognostic value of cell-free DNA (cfDNA) and circulating tumor cells (CTCs) have been less explored in SCLC.
Methods: We quantified cfDNA in 46 SCLC patients at different times during first-line of chemotherapy or chemo-immunotherapy. Moreover, CTCs were analyzed in 21 patients before therapy onset using CellSearch® system. The possible association between both biomarkers and patients' outcomes was investigated in order to develop a prognostic model.
Results: High cfDNA levels before therapy were associated with shorter progression-free survival (PFS) and overall survival (OS). Furthermore, cfDNA levels at 3 weeks and at progression disease were also associated with patients' outcomes. Multivariate analyses confirmed the independence of cfDNA levels as a prognostic biomarker. Finally, the three-risk category prognostic model developed included Eastern Cooperative Oncology Group Performance Status (ECOG PS), gender and baseline cfDNA levels was associated with a higher risk of progression and death.
Conclusions: We confirmed the prognostic utility of cfDNA quantitative analysis in SCLC patients before and during therapy. Our novel risk prognostic model in clinical practice will allow to identify patients who could benefit with actual therapies.
Small cell lung cancer (SCLC), which accounts for 15% of all lung cancer cases, is characterized by its aggressiveness, its strong association with tobacco and the poor outcome. About 70% of patients present extensive disease SCLC (ED-SCLC) where only 2% survive 5 years after diagnosis.[1–3] For many years, chemotherapy was the unique option to treat this tumor type. However, the scenario has changed in the last years. New therapies, such as immunotherapy, have been recently incorporated into the management of SCLC patients and, although some survival improvements have been reported in the patients with ED-SCLC,[4–8] the majority of them do not benefit from this new treatment. The genomic profile of SCLC is characterized by extensive chromosomal rearrangements and a high mutational burden, including in nearly all, inactivation of the tumor suppressor genes TP53 and RB1. However, nowadays the selection of treatment in SCLC patients is not dependent on the characteristics of the tumor, and the criteria to stratify patients is not clear, since no predictive biomarkers have been validated for the clinical practice. In this context, the use of liquid biopsies as a tool to guide treatment and/or for monitoring the patients' response represent a valuable alternative.[13,14]
Circulating tumor DNA (ctDNA), derived from tissue tumor cells, has demonstrated its clinical utility and represents a promising tool for guiding precision medicine in several cancer types.[15,16] In SCLC, different studies have investigated the importance and the clinical value of analyzing ctDNA levels. However, driver mutations known in SCLC are limited to RB1 and TP53 genes. In contrast, total cell-free DNA (cfDNA) consists of a heterogeneous and complex DNA fraction released in body fluids by any cell type through cell death mechanisms.[18,19] The short half-life of cfDNA enables real-time monitoring for response or relapse, being an easy-to-implement biomarker to monitor cancer evolution and response to therapy. In fact, in lung cancer and other solid tumors, cfDNA analysis has been explored as a prognostic marker and surrogate for monitoring treatment response.[21,22] High cfDNA level or positive ctDNA detection is clearly correlated tumor burden. Besides pre-treatment levels of ctDNA have value to predict long-term survival in locally advanced non-small cell lung cancer (NSCLC). Early cfDNA/ctDNA changes can be detected at first follow-up to predict radiographic response being their decreasing levels also been associated with improved survival rates as our group previously described in NSCLC.[24–26]
Circulating tumor cells (CTCs) are tumor cells originated from the primary or metastatic sites that are able to enter the circulation and disseminate to distant sites, and constitutes another frequent circulating biomarker investigated in cancer. As a high metastatic tumor type, SCLC is characterized by a strong release of CTCs, with detection rates of 60.2–94%, suggesting that CTCs could be employed as a disease surrogate in SCLC. The analysis of CTCs originated from the primary or metastatic sites as a prognostic biomarker has been reported in different cancer types[28–30] including SCLC. However, the prognostic threshold in SCLC has been not well established.[31–35] The low proportion of CTCs in the bloodstream together with the molecular heterogeneity that characterizes these cells is the principal challenge for CTC isolation and detection. For this reason, several platforms have been developed in the last years.[14,36] Despite their different nature, the combined analysis of total cfDNA and CTCs in patients with SCLC could provide complementary information for improving SCLC patients' management.
In this study, we hypothesized that total cfDNA levels can serve as a useful biomarker for prognostic and follow-up of SCLC patients under first line of therapy. For this purpose, we analyzed the total cfDNA levels in a cohort of 46 patients with SCLC prior to the start of therapy, at 3 weeks after the first dose, and at the time of progression of the disease. The additional value of CTCs was investigated in our cohort in order to provide a more complete view of the disease dynamics. Finally, we developed a simple model to segregate patients into three categories based on risk of progression and death (taking into account the cfDNA levels, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and gender of patients). To our knowledge, this study is the first one to examine the possible role of total cfDNA levels as a prognostic and follow-up biomarker in SCLC patients. We present this article in accordance with the REMARK reporting checklist (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-273/rc).
Transl Lung Cancer Res. 2022;11(10):1995-2009. © 2022 AME Publishing Company